首页> 美国卫生研究院文献>PLoS Clinical Trials >Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
【2h】

Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

机译:普伐他汀在高危老年人中的前瞻性研究中的血压变异性和心血管风险(PROSPER)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Variability in blood pressure predicts cardiovascular disease in young- and middle-aged subjects, but relevant data for older individuals are sparse. We analysed data from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study of 5804 participants aged 70–82 years with a history of, or risk factors for cardiovascular disease. Visit-to-visit variability in blood pressure (standard deviation) was determined using a minimum of five measurements over 1 year; an inception cohort of 4819 subjects had subsequent in-trial 3 years follow-up; longer-term follow-up (mean 7.1 years) was available for 1808 subjects. Higher systolic blood pressure variability independently predicted long-term follow-up vascular and total mortality (hazard ratio per 5 mmHg increase in standard deviation of systolic blood pressure = 1.2, 95% confidence interval 1.1–1.4; hazard ratio 1.1, 95% confidence interval 1.1–1.2, respectively). Variability in diastolic blood pressure associated with increased risk for coronary events (hazard ratio 1.5, 95% confidence interval 1.2–1.8 for each 5 mmHg increase), heart failure hospitalisation (hazard ratio 1.4, 95% confidence interval 1.1–1.8) and vascular (hazard ratio 1.4, 95% confidence interval 1.1–1.7) and total mortality (hazard ratio 1.3, 95% confidence interval 1.1–1.5), all in long-term follow-up. Pulse pressure variability was associated with increased stroke risk (hazard ratio 1.2, 95% confidence interval 1.0–1.4 for each 5 mmHg increase), vascular mortality (hazard ratio 1.2, 95% confidence interval 1.0–1.3) and total mortality (hazard ratio 1.1, 95% confidence interval 1.0–1.2), all in long-term follow-up. All associations were independent of respective mean blood pressure levels, age, gender, in-trial treatment group (pravastatin or placebo) and prior vascular disease and cardiovascular disease risk factors. Our observations suggest variability in diastolic blood pressure is more strongly associated with vascular or total mortality than is systolic pressure variability in older high-risk subjects.
机译:血压的变化预示着年轻和中年受试者的心血管疾病,但有关老年人的相关数据很少。我们分析了普伐他汀的前瞻性高危人群前瞻性研究(PROSPER)中的数据,研究对象为5804名年龄在70-82岁之间,有心血管疾病病史或危险因素的参与者。使用1年内至少进行5次测量来确定访视的血压变异性(标准差);最初的4819名受试者进行了为期3年的随访。对1808名受试者进行了长期随访(平均7.1年)。较高的收缩压变异性可独立预测长期的随访血管和总死亡率(收缩压标准偏差每增加5 mmHg,危险比= 1.2,95%置信区间1.1-1.4;危险比1.1,95%置信区间分别为1.1–1.2)。舒张压的变化与冠状动脉事件风险增加相关(危险度1.5,95%置信区间1.2-1.8,每增加5 mmHg),心力衰竭住院(危险度1.4,95%置信区间1.1-1.8)和血管(风险比为1.4,95%的置信区间为1.1-1.7)和总死亡率(风险比1.3,95%的置信区间为1.1-1.5),所有这些都需要长期随访。脉压变异性与卒中风险增加(每增加5 mmHg危险比1.2,95%置信区间1.0-1.4),血管死亡率(危险比1.2,95%置信区间1.0-1.3)和总死亡率(危险比1.1)相关。 ,95%置信区间1.0-1.2),所有这些都需要长期随访。所有关联均独立于各自的平均血压水平,年龄,性别,审判治疗组(普伐他汀或安慰剂)以及先前的血管疾病和心血管疾病危险因素。我们的观察结果表明,与老年高危受试者的收缩压变异性相比,舒张压变异性与血管死亡率或总死亡率的相关性更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号